Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- FMT to Reduce ASCT Side Effects?
FMT to Reduce ASCT Side Effects?
Fecal microbiota transplantation (FMT) to reduce autologous stem cell transplant (ASCT) side effects? Also possibly enhancing PFS and OS? Yes, this might sound… off-putting. But let me explain.
The two key issues that readers must understand are:
- ASCT harms microbiome diversity before and after treatment
- Microbiome diversity helps MM patients live longer post ASCT
Faecal Microbiota Transplantation (FMT) Supporting Cancer Treatment – Summary
While the study linked below raises the issue of FMT post-ASCT to help patients live with fewer side effects and possibly longer tells me that our gut microbiota diversity is the issue. Not necessarily how we increase our gut microbiota diversity.
I mean, if every MM patient about to have an ASCT ate yogurt, supplemented with prebiotics in the form of polyphenols and underwent acupuncture to enhance their gut microbiome, these MM patients could achieve the same enhanced ASCT outcome as if they underwent FMT, right?
Let’s leave it this way. MM patients undergoing an ASCT should undergo evidence-based therapies to enhance their gut microbiome such as-
- Yogurt, kimchi, etc.
- Polyphenols,
- FMT,
- Acupuncture
Email me at David.PeopleBeatingCancer@gmail.com to learn more about both conventional and evidence-based non-conventional MM therapies.
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study
Abstract
Background: The composition of the gut microbiota both prior to and after haematopoietic stem cell transplantation (HSCT) is increasingly implicated in the outcomes of HSCT, including
- infections,
- poor immune reconstitution and
- disease relapse.
Faecal microbiota transplantation (FMT) offers a potential strategy of supporting the gut microbiota and improve HSCT outcomes. Although FMT has been investigated in HSCT recipients, it has largely been evaluated therapeutically for indications such as infection, or once immunocompetency is regained.
Methods: Peri-HSCT FMT (i.e. before and after HSCT) will be administered to eligible participants (adults undergoing autologous HSCT for a haematological malignancy) over two courses, with the first delivered immediately prior to conditioning and the second starting when ANC > 0.8. Following an open-label, safety run in (N = 5), peri-HSCT FMT will be evaluated for its efficacy in 51 participants, randomised 2:1 to FMT or placebo. The primary outcome is the proportion of participants who develop severe gastrointestinal toxicity defined by 3 consecutive days of severe diarrhoea (Bristol Stool Chart 6+), at a frequency of 4 + bowel movements/day within 3 weeks of HSCT. Safety is defined as the incidence of treatment-emergent adverse events (TE-AEs). Tolerability is defined as the incidence of TE-AEs and adherence to FMT.
Discussion: The HSCT-BIOME study is a multi-centre, double-blind, randomised placebo-controlled trial designed to determine the tolerability, safety and efficacy of orally-administered encapsulated FMT to promote the stability of the gastrointestinal microenvironment for HSCT recipients.
Peri-HSCT delivered FMT is hypothesised to promote microbial composition both before and following HSCT. Thus, the study will determine if administration of FMT post-HSCT during the neutropenic phase will enhance efficacy.
FMT to reduce ASCT side effects FMT to reduce ASCT side effects FMT to reduce ASCT side effects